PRTA Prothena Corporation plc

$PRTA below are the drugs they are making. I like all of it and hope all of it work. My family need these and willing to pay to give a try. • Prasinezumab (for Parkinson's): Acts like a shield to stop a bad protein (α-synuclein) from spreading and damaging brain cells. (Partnered with Roche) • Coramitug (for Heart Disease): Targets misfolded proteins that build up in the heart and cause a rare, dangerous stiffness. (Partnered with Novo Nordisk) • Moponetug (for Alzheimer's): Aims to stop a protein called "Tau" from creating toxic tangles inside brain cells. (Partnered with Bristol Myers Squibb) • PRX012 (for Alzheimer's): Designed to clear out the sticky plaques that block brain signals, though early tests showed it can cause some brain swelling side effects.

$PRTA update on our Oct 19 pick: 10% holder William Scully bought another 140,000 shares on the open market on 9 Nov at about 8.53, about 1.19M in all. He holds 977,000 directly after gifting about 916K on 6 Nov. Our pick price was 8.35. Form 4: https://www.sec.gov/Archives/edgar/data/1045463/000104546326000024/xslF345X06/primary_doc.xml

$PRTA update on our Oct 19 pick Prothena. Q3 R&D fell to 8.4M from 28.9M a year ago and the net loss narrowed to 16.5M from 36.5M, though Q3 revenue was only 0.6M vs 2.4M. Cash and equivalents were 271.4M at Sep 30, down from 307.5M in December, and the company has bought back 2.75M shares this year for 26.6M (501K in Q3). No debt. It guides to about 259M of cash at year end, not counting any further buybacks. The 100M buyback program expires Dec 31. Does it get renewed? Filing: https://www.sec.gov/Archives/edgar/data/1559053/000155905326000030/exhibit991q32026earningsre.htm

$PRTA 🚨 TESTING INSTITUTIONAL BUY ZONE | $9 CALL SWEEP 🚨 $PRTA is compressing inside its $8.20 – $8.80 Institutional Buy Zone on the 8H chart! Wedge apex compression holding strong as unexpired call sweep hits demand. 📊 CHART ZONES & FLOW ($PRTA, 8H): • Smart Money Sell: $10.20 – $11.00 • Institutional Sell: $9.40 – $10.00 • Institutional Buy: $8.20 – $8.80 (CURRENT LOAD) • Smart Money Buy: $7.80 – $8.15 • Active Flow: $50.5K sweep on 12/18 $9 Calls @ Ask ($0.60) 🎯 KEY LEVELS: 🐂 Bull Trigger: Defend $8.00 & reclaim $9.00 to target $9.80+. 🐻 Bear Trigger: 8H close below $7.75. BIAS: Tactical Wedge Reversal / Long off Demand 📊📈 #hovdid

$PRTA update on our oct 19 pick: Bristol Myers told Prothena on oct 28 it won't take PRX019 any further in the clinic. the license ends jan 28 2027, and the up to about 618M of milestones on it, plus royalties, are gone, including the 55M payment we flagged. what hasn't changed: the 2026 cash guidance never counted that 55M, and BMS is still running the phase 2 alzheimer's trial of moponetug (135M paid so far, up to about 563M of milestones left). once the license ends, does Prothena try to partner PRX019 again? Filing: https://www.sec.gov/Archives/edgar/data/1559053/000155905326000026/prta-20261028.htm